Latest news with #MNMD
National Post
28-05-2025
- Business
- National Post
MindMed to Participate in June Investor Conferences
Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Article content Article content Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days following each event. Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Article content Article content Article content
National Post
13-05-2025
- Business
- National Post
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: Article content 2025 RBC Capital Markets Global Healthcare Conference Format: Fireside Chat and 1×1 Meetings Date: May 21, 2025, at 2:05 PM ET Location: New York, NY Webcast Link: 2025 RBC Capital Markets Global Healthcare Conference Article content Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days following each event. Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD. Article content Article content Article content Article content Article content
National Post
24-04-2025
- Business
- National Post
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025
Article content NEW YORK — Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Article content Article content Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Article content Article content Article content
